Immortagen, Inc.

Immortagen, Inc. is a biotechnology firm specializing in enhancing cellular therapies and regenerative medicine through proprietary tools and technologies, aimed at addressing key medical challenges. Founded in 2014 in Coralville, US, Immortagen, Inc. focuses on advanced biotechnology solutions.

The company has executed two deals, with its most recent funding round being a Grant of USD 0. 010 mn from the Iowa Economic Development Authority in September 2016. The founders include Baoli Yang, Don Dai, Donghai Dai, and Kristi Thiel, contributing diverse expertise to the company’s growth. Immortagen.

com specializes in advanced biotechnology solutions focused on enhancing cellular therapies and regenerative medicine. The company’s core offerings include a suite of proprietary tools and technologies designed to optimize the development and delivery of cellular therapies. These services aim to address critical challenges in the medical field, including the scalability of cell production and the enhancement of therapeutic efficacy. Immortagen serves a diverse client base that encompasses research institutions, biotech companies, and healthcare providers across North America and Europe.

The company’s products are instrumental in facilitating breakthroughs in personalized medicine, targeting a range of conditions from autoimmune diseases to cancer. Immortagen generates revenue primarily through direct sales of its biotechnology products and services to B2B clients, which include pharmaceutical companies and research institutions. The company operates on a transaction structure that involves both one-time purchases and ongoing service agreements, enabling clients to integrate Immortagen’s technologies into their existing workflows. Pricing plans for its flagship products are structured to reflect the sophisticated nature of its offerings, allowing for tailored packages based on client needs and project scale.

This strategic approach not only fosters long-term partnerships but also positions Immortagen as a critical player in the rapidly evolving landscape of cellular therapies. Immortagen plans to leverage its recent funding to develop new products and enhance its market presence. The company is focused on launching innovative tools aimed at improving the efficiency of cellular therapies, with specific product releases anticipated in the coming years. Additionally, Immortagen is targeting expansion into European markets to broaden its client base and impact, which is expected to commence following the next product launch.

Recent funding will support these initiatives, allowing the company to invest in research and development efforts.